Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Biol Blood Marrow Transplant. 2011 Feb;17(2):157-66. doi: 10.1016/j.bbmt.2010.07.009. Epub 2010 Jul 24.
Preservation of fertility after hematopoietic cell transplantation (HCT) can have a significant influence on the quality of life of transplant survivors. We describe 178 pregnancies in HCT recipients that were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2002 and 2007. There were 83 pregnancies in female HCT recipients and 95 pregnancies in female partners of male HCT recipients. Indications for transplantation included hematologic and other malignancies (N = 99) and nonmalignant disorders (N = 79, of which 75 patients had severe aplastic anemia). The cohort included recipients of autologous HCT (20 women, 13 men), myeloablative (MA) allogeneic HCT (12 women, 50 men), and nonmyeloablative allogeneic HCT (2 women, 2 men). Age at HCT was <20 years for 50% of women and 19% of men. Conditioning regimens included total body irradiation (TBI) in 16% of women and 19% of men; doses were MA in 10% of women and in 16% of men. Live births were reported in 86% of pregnancies in partners of male transplant patients and 85% of pregnancies in female transplant patients, with most pregnancies occurring 5 to 10 years after HCT. We conclude that some HCT recipients can retain fertility, including patients who have received TBI and/or MA conditioning. Young patients undergoing HCT should be counseled both before and after HCT about potential loss of fertility, methods for preserving fertility, and planning for future pregnancy. Fertility and outcomes of pregnancy after HCT need prospective evaluation in large transplant cohorts.
造血细胞移植(HCT)后保留生育能力可以对移植幸存者的生活质量产生重大影响。我们描述了 2002 年至 2007 年期间向国际血液和骨髓移植研究中心(CIBMTR)报告的 178 例 HCT 受者的妊娠情况。女性 HCT 受者中有 83 例妊娠,男性 HCT 受者的女性伴侣中有 95 例妊娠。移植的适应症包括血液系统和其他恶性肿瘤(N=99)和非恶性疾病(N=79,其中 75 例患者患有严重再生障碍性贫血)。该队列包括自体 HCT 受者(20 名女性,13 名男性)、清髓性(MA)异基因 HCT 受者(12 名女性,50 名男性)和非清髓性异基因 HCT 受者(2 名女性,2 名男性)。女性的 HCT 年龄<20 岁的占 50%,男性的占 19%。预处理方案包括女性 16%和男性 19%的全身照射(TBI);MA 剂量在女性中占 10%,在男性中占 16%。男性移植患者伴侣的 86%和女性移植患者的 85%的妊娠报告了活产,大多数妊娠发生在 HCT 后 5 至 10 年。我们得出结论,一些 HCT 受者可以保留生育能力,包括接受 TBI 和/或 MA 预处理的患者。接受 HCT 的年轻患者应在 HCT 前和 HCT 后接受咨询,内容包括潜在的生育能力丧失、保留生育能力的方法以及未来妊娠计划。HCT 后生育能力和妊娠结局需要在大型移植队列中进行前瞻性评估。